MMWR Morb Mortal Wkly Rep. 2006 Apr 7;55(13):364-6.
In October 2005, a possible association between Guillain-Barré Syndrome (GBS) and receipt of meningococcal conjugate vaccine (i.e., meningococcal polysaccharide diphtheria toxoid conjugate vaccine [Menactra]) (MCV4) was reported. GBS is a serious neurologic disorder involving inflammatory demyelination of the peripheral nerves. At the time of the first report, five confirmed cases of GBS after receipt of MCV4 had been reported to the Vaccine Adverse Events Reporting System (VAERS). During the 4 months since, three additional confirmed cases of GBS have been reported. This report describes two of these recent cases and provides additional data collected through February 2006. Because available evidence neither proves nor disproves a causal relation between MCV4 and GBS, further monitoring and studies are ongoing within VAERS and the Vaccine Safety Datalink (VSD). CDC continues to recommend use of MCV4 for persons for whom vaccination is indicated; the additional reported cases have not resulted in any change to that recommendation.
2005年10月，有报告称格林-巴利综合征（GBS）与接种脑膜炎球菌结合疫苗（即脑膜炎球菌多糖白喉类毒素结合疫苗[美奈喜]）（MCV4）之间可能存在关联。GBS是一种严重的神经系统疾病，涉及周围神经的炎性脱髓鞘。在首次报告时，已有5例接种MCV4后确诊为GBS的病例报告至疫苗不良事件报告系统（VAERS）。在此后的4个月里，又报告了3例确诊的GBS病例。本报告描述了其中2例近期病例，并提供了截至2006年2月收集的更多数据。由于现有证据既不能证实也不能排除MCV4与GBS之间的因果关系，VAERS和疫苗安全数据链（VSD）正在进行进一步监测和研究。美国疾病控制与预防中心（CDC）继续建议为有接种指征的人群使用MCV4；新增报告病例未导致该建议发生任何改变。
